O2 Cross-validation of HIV DNA assays to quantify different HIV-1 subtypes by ddPCR

by S. Rutsaert, W. Trypsteen, C. Van Hecke, M.A. De Scheerder, M. Kiselinova, K. Vervisch, W. De Spiegelaere, L. Vandekerckhove
Published 2016-09-01

Impact of a decade of sustained antiretroviral therapy started during HIV-1 seroconversion on blood and gut reservoirs

by S. Kinloch, E. Malatinkova, W. De Spiegelaere, P. Bonczkowsk, M. Kiselinova, K. Vervisch, W. Trypsteen, M. Johnson, D. de Looze, L. Vandekerckhove
Published 2015-12-01

O5 The expression profile of host restriction factors in different cohorts of HIV-1-infected patients

by C. Van Hecke, E. Malatinkova, W. De Spiegelaere, M. Sips, K. Vervisch, C. Verhofstede, M. Johnson, S. Kinloch-de Loës, W. Trypsteen, L. Vandekerckhove
Published 2017-09-01

O7 Does viral suppressive capacity in cART-treated HIV-infected patients correlate with disease parameters, viral reservoir measures or cytotoxic T cell phenotype?

by P. Pannus, P. Adams, E. Willems, L. Heyndrickx, M. Van Frankenhuijsen, E. Florence, M. Kiselinova, S. Rutsaert, K. Vervisch, W. Despiegelaere, C. Devaux, L. Vandekerckhove, G. Vanham
Published 2017-09-01